• Explore /
  • Poster
  • / A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.

A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.

Abstract Poster

Authors

null

Kim Schellekens

Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital and Princess Máxima Center for Pediatric Oncology, Rotterdam, Netherlands

Kim Schellekens , Reineke Anna Schoot , Natasha K.A. van Eijkelenburg , Alwin Huitema , Michela Casanova , Dirk Reinhardt , Lynley V. Marshall , Isabelle Aerts , Giuseppe Barone , Louis Chesler , Jennifer Tall , Debbie Hughes , Rana Dandis , Lucas Moreno , Pauline L.H. Winkler-Seinstra , Keith D. Wilner , C Michel Zwaan , Jasper van der Lugt

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

2015-005437-53

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 10036)

DOI

10.1200/JCO.2023.41.16_suppl.10036

Abstract #

10036

Poster Bd #

342

Abstract Disclosures

Similar Posters

First Author: Kelly C. Goldsmith

First Author: Rochelle Bagatell

First Author: T. R. Hummel

First Author: Wang Yk